[Clinical experiences of LAK therapy in patients with hepatocellular carcinoma].
A patient with hepatocellular carcinoma (HCC) was treated with newly established adoptive immunotherapy using LAK cells (LAK therapy) together with transcatheter arterial embolization therapy (TAE). This patient responded well, and the therapeutic efficacy still continues 6 months after the therapy. Since the efficacy of LAK therapy does not last long, it is recommended that LAK therapy should be employed in combination with such therapeutic maneuvers as TAE or anticancer drugs in patients with HCC.
Zeki
K
K
Unit of Blood Transfusion Service, University Hospital, University of Occupational and Environmental Health, Kitakyushu, Japan.
Sakamoto
H
H
Okuno
F
F
Sujita
K
K
Eto
S
S
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D006801:Humans; D007116:Immunization, Passive; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male